AN2 Therapeutics to pause lung disease study enrollment

AN2 Therapeutics

12/02/2024 11:54

Feb 12 (Reuters) - AN2 Therapeutics  ANTX.O  said on
Monday it will pause further enrollment in a mid-to-late-stage
study testing its experimental drug to treat a type of bacterial
lung infection, citing potentially lower-than-expected efficacy.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna
Chandra Eluri)
 ((Mariam.ESunny@thomsonreuters.com;))